VolitionRx Limited has announced a significant advancement in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA from blood samples. The company's Capture-Seq platform successfully addresses the persistent challenge of distinguishing cancer DNA from healthy cell-free DNA, a critical barrier in liquid biopsy development. Early validation results show no false positives and successful detection across initial study cohorts, indicating strong potential for this novel biomarker approach.
The breakthrough could enable transformative applications in multi-cancer early detection and minimal residual disease monitoring. These applications represent a combined total addressable market of approximately $36 billion, according to company estimates. The ability to detect cancer DNA with such high specificity could lead to earlier interventions and improved patient outcomes across various cancer types.
The advancement represents a potential paradigm shift in cancer diagnostics, moving beyond traditional tissue biopsies to less invasive blood-based testing. Liquid biopsies have been limited by the difficulty of isolating minute amounts of cancer DNA from the vast background of normal DNA circulating in blood. VolitionRx's achievement of over 99% purity suggests their technology may overcome this fundamental limitation.
While the technology shows promise, further validation in larger clinical studies will be necessary to confirm its clinical utility. The company's approach focuses on epigenetics, the study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence. This epigenetic focus may provide advantages in detecting cancer-specific markers that are more stable and abundant than genetic mutations alone.
The liquid biopsy market has seen rapid growth in recent years, with applications expanding from cancer monitoring to early detection. VolitionRx's breakthrough could position the company competitively in this expanding field. The technology's potential extends beyond human medicine, as the company is also developing applications for animal health through its subsidiary operations.
VolitionRx is currently engaged in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. The company's research and development activities are centered in Belgium, with additional facilities in the United States and United Kingdom. For further information about the company's work, visit https://volition.com/.
